AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03173287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantification of liver fibrosis
Description: Procedure MRI and liver biopsy
Study NCT00289120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cola beverage
Description: Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
Study NCT00289120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deionized water
Description: Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
Study NCT04302038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Additional daily protein provided by potato protein.
Study NCT04302038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: No additional dietary protein (outside of 0.8 g/kg/day as provided by diet)
Study NCT02940808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Caffeine (200mg)
Description: Oral consumption of capsule containing 200mg caffeine.
Study NCT02940808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Oral consumption of capsule containing a placebo substance.
Study NCT01144247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alloreactive CTL
Description: cellular immunotherapy with alloCTL
Study NCT01507766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early enteral nutrition
Description: The enteral nutrition was started within 48h after admission
Study NCT04817059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caseforge headcase
Description: We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
Study NCT01507766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delayed enteral nutrition
Description: The enteral nutrition was started at the 8th day after admission
Study NCT06304168 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT02192190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC
Study NCT04740840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine
Description: According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
Study NCT04740840 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Amlodipine
Description: According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
Study NCT00808535 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Perfusion MRI w Vasomotor Stress
Description: All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
Study NCT01386242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-tumor and anti-virus protein for injection
Description: Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
Study NCT01386242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-tumor and anti-virus protein for injection
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
Study NCT01386242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Saline Injection, 1mL, im,three times per week
Study NCT01386242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-tumor and anti-virus protein for injection
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
Study NCT02770976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Increasing and decreasing NAVA levels with 10-min intervals
Study NCT03009838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: oral tablets 2.5 mg
Study NCT03009838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ovarian drilling
Description: laparoscopic electrocauterization
Study NCT03236012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (Botox)
Description: Maximum dose up to 400 units given one time
Study NCT00711490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
Study NCT01333670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prontosan wound irrigation solution
Description: * cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~* dressing with Prontosan Wound Irrigation solution
Study NCT01333670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic solution (saline or lactated ringer)
Description: * cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~* dressing with isotonic solution
Study NCT03300843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide loaded dendritic cell vaccine
Description: On days 0, 14 (+/- 5 days), 28 (+/- 5 days), and 42 (+/- 5 days). The vaccine will be administered as both an intravenous (IV) infusion and a subcutaneous (SQ) injection. The total dose will be divided equally between intravenous (IV) and SQ containing 1.0E7 to 8.0E7 cells per cycle depending upon the manufacturing yield.
Study NCT02875691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green tea extract
Description: Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
Study NCT02875691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
Study NCT00311324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Intervention
Study NCT03749096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Immunoglobulins, Human
Description: Immunoglobulins are fractionated blood products made from pooled human plasma.
Study NCT03749096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline
Study NCT03352583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: 40g calcium caseinate
Study NCT03352583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: 40g calcium caseinate
Study NCT00311324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Intervention
Study NCT01006018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Pioglitazone PLACEBO
Description: Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
Study NCT01006018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Pioglitazone
Description: Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
Study NCT02142725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: four times per day
Study NCT03451344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based rehabilitation group
Description: Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
Study NCT01012518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCT
Description: The standard technique, performed without video guidance
Study NCT02142725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: two times per day
Study NCT02142725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: four times per day
Study NCT01006018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
Study NCT02782806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Rad-67 Pulse Oximeter
Description: Noninvasive pulse oximeter
Study NCT01449370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: oral administration of TAK-117, daily and intermittent schedules.
Study NCT02008435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched GLB
Description: Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
Study NCT02008435 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard GLB
Description: This arm is the standard Group Lifestyle Balance program
Study NCT02508129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia
Description: BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.
Study NCT02508129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet
Description: SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure.
Study NCT02508129 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
Study NCT01971437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystodistension & Cystoscopy
Description: Women with refractory OAB receiving Cystoscopy and cystodistension
Study NCT01971437 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cystodistension & Cystoscopy
Description: Women with refractory OAB receiving Cystoscopy and cystodistension
Study NCT03150407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR101 Device (Efficacy)
Description: Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days
Study NCT03150407 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control Ring
Description: Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days
Study NCT03150407 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VR101 Device (Safety)
Description: Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.
Study NCT02053337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self adhesive foam dressing
Description: Self adhesive foam dressing
Study NCT02053337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self adhesive foam dressing
Description: Self adhesive foam dressing
Study NCT00735618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Relaxation
Description: Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
Study NCT00428116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: Combination first line antiretrovirals as previously described.
Study NCT03629197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication skills training
Description: Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
Study NCT03629197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Physician will review materials based on CDC opioid prescribing guidelines.
Study NCT02564887 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Iowa Oral Performance Instrument
Description: the IOPI device is being used to increase tongue strength and endurance
Study NCT02564887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iowa Oral Performance Instrument
Description: the IOPI device is being used to increase tongue strength and endurance
Study NCT02341391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(Low dose)
Description: 3.0 x 10\^6 cells
Study NCT02341391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(Medium dose)
Description: 1.0 x 10\^7 cells
Study NCT02341391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(High dose)
Description: 3.0 x 10\^7 cells
Study NCT04787679 — intervention group
Intervention type: PROCEDURE
Intervention: Hip replacement surgery
Description: After hip replacement surgery the sponsor obtains femoral head samples for the study
Study NCT03593538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsule
Study NCT03593538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose filler in gel capsules
Study NCT03593538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucrose filler in gel capsules
Study NCT01012518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-guided PCT
Description: PCT performed with the guidance of a camera-embedded ETT wired to a monitor
Study NCT01575665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Partial Rebreathing Mask
Description: Inducing normal CO2 for two hours a day for four weeks
Study NCT01859910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: compression and scrub of lid margin
Description: compression and scrub of lid margin for 5 circles before cataract surgery
Study NCT01859910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine preparation for cataract
Study NCT01859910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine preparation for cataract
Study NCT03909295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
Study NCT01951742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1401
Description: Active
Study NCT01763320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracranial stenting group
Description: all the participants in this group will be performed with intracranial stenting
Study NCT01763320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical group
Description: all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
Study NCT02109874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404 (mcg H4/nmol IC31)
Description: Dose escalation
Study NCT02109874 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl
Study NCT03723174 — intervention group
Intervention type: BEHAVIORAL
Intervention: Oral Health Educational Program
Description: proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
Study NCT02535286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: A once daily oral agent
Study NCT02535286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ublituximab
Description: IV anti-CD20 monoclonal antibody
Study NCT02535286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG-1501
Description: IV immunotherapy for cancer
Study NCT03391726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CART-19 cells
Description: CART-19 cells treat
Study NCT02264860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Zinc and SAMe
Description: The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
Study NCT00567684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed Tomography Urography (CTU)
Description: CTU performed at least a day before or after the IVU procedure.
Study NCT00567684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Urography (IVU)
Description: A routine IVU procedure performed prior to or after CTU.
Study NCT00658047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH-1504
Description: Comparison of different doses of CH-1504
Study NCT03624426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Somatosensory Evoked Potential device (EPAD@)
Description: After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
Study NCT02675192 — intervention group
Intervention type: OTHER
Intervention: Proof cohort : muscular assessment
Description: Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
Study NCT01951742 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study NCT02066740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EverFlex™ stent with Entrust™ delivery system